Xingsong Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xingsong Tian has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Qing Yang
Shandong University, Cheeloo College of Medicine, Jinan, Shandong, China
6 shared publicationsTianyi Dong
Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University
4 shared publicationsNingning Ren
Shandong Prov Hosp, Dept Breast & Thyroid Surg, 324 Jing 5 Rd, Jinan 250021, Shandong, Peoples R China
3 shared publications- Ningning Ren
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
3 shared publications Peikai Ding
School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
3 shared publications- Xingchen Shang
Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (5)
Analysis and Identification of Candidate Genes Associated with M1 Macrophage Infiltration and Glycolysis in Breast Cancer
Macrophage polarization and glycolytic reprogramming contribute to the breast cancer microenvironment. However, the genes associated with these features and their clinical relevance remain poorly defined. Breast cancer transcriptomic datasets were analyzed using immune deconvolution, single‐sample gene set enrichment analysis, and weighted gene coexpression network analysis. We identified 101 genes shared by the M1 macrophage‐associated, glycolysis‐related, and differentially expressed gene sets. Eight genes showed suggestive genetically predicted associations with BC risk. Machine learning selected seven consensus genes. In TCGA‐BRCA, six genes differed significantly between tumor and normal tissue, but only five changed in the same direction as in GSE65194. In the 56 paired clinical tissues, ADAM15, PPP1R14B, and XPO5 were upregulated in tumors, whereas FAM172A and PPM1M were downregulated. ADAM15, PPP1R14B, and XPO5 were preferentially expressed in M1‐like TAMs, whereas FAM172A and PPM1M showed higher expression in M2‐like TAMs. In BMDMs, overexpression of ADAM15, XPO5, or PPP1R14B, as well as knockdown of PPM1M or FAM172A, increased the proportion of CD80‐positive cells and ATP, glucose uptake, and lactate production. Five genes showed significant associations with overall survival. Functional enrichment analyses implicated immune regulation, extracellular matrix organization, and metabolic pathways.
- 5 November 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (5)
Open AccessAnalysis and Identification of Candidate Genes Associated with M1 Macrophage Infiltration and Glycolysis in Breast Cancer
Macrophage polarization and glycolytic reprogramming contribute to the breast cancer microenvironment. However, the genes associated with these features and their clinical relevance remain poorly defined. Breast cancer transcriptomic datasets were analyzed using immune deconvolution, single‐sample gene set enrichment analysis, and weighted gene coexpression network analysis. We identified 101 genes shared by the M1 macrophage‐associated, glycolysis‐related, and differentially expressed gene sets. Eight genes showed suggestive genetically predicted associations with BC risk. Machine learning selected seven consensus genes. In TCGA‐BRCA, six genes differed significantly between tumor and normal tissue, but only five changed in the same direction as in GSE65194. In the 56 paired clinical tissues, ADAM15, PPP1R14B, and XPO5 were upregulated in tumors, whereas FAM172A and PPM1M were downregulated. ADAM15, PPP1R14B, and XPO5 were preferentially expressed in M1‐like TAMs, whereas FAM172A and PPM1M showed higher expression in M2‐like TAMs. In BMDMs, overexpression of ADAM15, XPO5, or PPP1R14B, as well as knockdown of PPM1M or FAM172A, increased the proportion of CD80‐positive cells and ATP, glucose uptake, and lactate production. Five genes showed significant associations with overall survival. Functional enrichment analyses implicated immune regulation, extracellular matrix organization, and metabolic pathways.
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (8) , 231
Influencing factors and prediction model of ultrasound-based false-negative central lymph node metastasis in localized papillary thyroid carcinoma
Background: Patients with papillary thyroid cancer (PTC) exhibited a high false-negative rate for central lymph nodes (CLNs), with unknown influencing factors and predictive models. This study aimed to identify risk factors for false-negative CLN findings in a cohort study and to develop a predictive model to support clinical decision-making. Methods: This cohort study included patients admitted to the Breast and Thyroid Surgery Department of Shandong Provincial Hospital, China, between January 2013 and December 2023. All patients included in the study were confirmed to papillary thyroid cancer (TC) based on postoperative paraffin-embedded pathology. False-negative CLNs refers to metastasis undetected by preoperative ultrasound but confirmed postoperatively by pathology. Logistic regression, forest graph and nomogram were used to calculate and display statistical difference between influencing factors and the false-negative rate of CLNs. Results: A total of 5,614 patients with papillary TC [44.19±11.14 years, 4,469 women (79.6%)] were analyzed. Logistic regression analysis showed that gender [odds ratio (OR): 1.832, 95% confidence interval (CI): 1.570–2.137, PConclusions: This cohort study indicated that the false-negative rate of CLNs was quite common. Personalized preventive CLN dissection was suggested.
- 1 August 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (8) , 231
Open AccessInfluencing factors and prediction model of ultrasound-based false-negative central lymph node metastasis in localized papillary thyroid carcinoma
Background: Patients with papillary thyroid cancer (PTC) exhibited a high false-negative rate for central lymph nodes (CLNs), with unknown influencing factors and predictive models. This study aimed to identify risk factors for false-negative CLN findings in a cohort study and to develop a predictive model to support clinical decision-making. Methods: This cohort study included patients admitted to the Breast and Thyroid Surgery Department of Shandong Provincial Hospital, China, between January 2013 and December 2023. All patients included in the study were confirmed to papillary thyroid cancer (TC) based on postoperative paraffin-embedded pathology. False-negative CLNs refers to metastasis undetected by preoperative ultrasound but confirmed postoperatively by pathology. Logistic regression, forest graph and nomogram were used to calculate and display statistical difference between influencing factors and the false-negative rate of CLNs. Results: A total of 5,614 patients with papillary TC [44.19±11.14 years, 4,469 women (79.6%)] were analyzed. Logistic regression analysis showed that gender [odds ratio (OR): 1.832, 95% confidence interval (CI): 1.570–2.137, PConclusions: This cohort study indicated that the false-negative rate of CLNs was quite common. Personalized preventive CLN dissection was suggested.
- Open Access
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1778949
Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis
Introduction: Thyroid cancer represents the most prevalent malignancy of the endocrine system, with papillary thyroid carcinoma (PTC) accounting for approximately 90% of cases. Hashimoto’s thyroiditis (HT) is a common benign thyroid disorder, frequently associated with structural alterations in thyroid morphology. Evidence indicated that HT may be a risk factor for the development of PTC. Exosomes promote intercellular communication by transferring proteins, mRNAs, micro-RNAs (miRNAs), and lipids to recipient cells, rendering them potential sources of disease-specific biomarkers. Methods: This study employed an integrative approach, combining exosome isolation, proteomics, and bioinformatics to identify plasma-derived exosomal biomarkers associated with PTC in the context of HT. Plasma samples were obtained from three patients each with PTC, PTC associated with HT (PTC-W), HT, and healthy controls (HCs). Exosomal proteins were extracted and analyzed using label-free quantitative proteomics. Results: A total of 45 differentially expressed proteins (DEPs) were identified between PTC-W and HT. Functional annotation and enrichment analyses revealed that these DEPs were predominantly implicated in extracellular matrix (ECM)–receptor interactions and immune response pathways. Subsequent validation via parallel reaction monitoring (PRM) confirmed that SVEP1 and IGKV3-7 exhibited consistent and statistically significant expression levels across discovery and validation phases. Discussion: These results highlight SVEP1 and IGKV3-7 as promising plasma exosomal biomarkers for PTC in patients with HT, providing mechanistic insights into the progression from HT to PTC and potential utility for non-invasive clinical diagnosis.
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1778949
Open AccessIntegrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis
Introduction: Thyroid cancer represents the most prevalent malignancy of the endocrine system, with papillary thyroid carcinoma (PTC) accounting for approximately 90% of cases. Hashimoto’s thyroiditis (HT) is a common benign thyroid disorder, frequently associated with structural alterations in thyroid morphology. Evidence indicated that HT may be a risk factor for the development of PTC. Exosomes promote intercellular communication by transferring proteins, mRNAs, micro-RNAs (miRNAs), and lipids to recipient cells, rendering them potential sources of disease-specific biomarkers. Methods: This study employed an integrative approach, combining exosome isolation, proteomics, and bioinformatics to identify plasma-derived exosomal biomarkers associated with PTC in the context of HT. Plasma samples were obtained from three patients each with PTC, PTC associated with HT (PTC-W), HT, and healthy controls (HCs). Exosomal proteins were extracted and analyzed using label-free quantitative proteomics. Results: A total of 45 differentially expressed proteins (DEPs) were identified between PTC-W and HT. Functional annotation and enrichment analyses revealed that these DEPs were predominantly implicated in extracellular matrix (ECM)–receptor interactions and immune response pathways. Subsequent validation via parallel reaction monitoring (PRM) confirmed that SVEP1 and IGKV3-7 exhibited consistent and statistically significant expression levels across discovery and validation phases. Discussion: These results highlight SVEP1 and IGKV3-7 as promising plasma exosomal biomarkers for PTC in patients with HT, providing mechanistic insights into the progression from HT to PTC and potential utility for non-invasive clinical diagnosis.
- Open Access
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44960
Comparing adverse events of Saphnelo and Benlysta: A real-world observational study based on the FDA adverse event reporting system (FAERS) following STROBE guidelines
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease. In recent years, biologic agents have provided new treatment options for SLE. This study aims to conduct a comparative analysis of the adverse drug events (AEs) associated with anifrolumab (Saphnelo) and belimumab (Benlysta). AEs were extracted from the FDA adverse event reporting system (FAERS) for the period from April 2011 to April 2024. A total of 21,631 cases were collected from the FAERS system (20,819 for belimumab, 812 for anifrolumab). In terms of injury, poisoning, and procedural complications, anifrolumab was more prone to infusion-related reactions (ROR 6.64), while belimumab exhibited unique AEs such as product dose omissions (ROR 12.63), improper device usage techniques (ROR 20.66), and exposure via skin contact (ROR 80.18). In the category of infections and infestations, anifrolumab was more likely to cause herpes zoster (ROR 21.91), whereas belimumab was more commonly associated with influenza (ROR 2.75). Regarding nervous system disorders, anifrolumab showed a higher incidence of headache (ROR 2.83). In skin and subcutaneous tissue disorders, anifrolumab demonstrated strong signals for rash (ROR 2.29). More severely, anifrolumab was associated with a higher risk of pericarditis (ROR 7.92). Additionally, anifrolumab may lead to psychiatric, vascular, renal, and urinary disorders, primarily presenting as confusional state (ROR 2.14), flushing (ROR 2.94), and proteinuria (ROR 10.96). The adverse reactions associated with belimumab are primarily linked to operational factors (such as product dose omissions) and injection site issues (e.g., injection site pain and hemorrhage). AE reports for anifrolumab demonstrated significant complexity and diversity. Enhanced patient monitoring and therapy optimization are urgently required to ensure more effective management of SLE while minimizing risks.
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44960
Open AccessComparing adverse events of Saphnelo and Benlysta: A real-world observational study based on the FDA adverse event reporting system (FAERS) following STROBE guidelines
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease. In recent years, biologic agents have provided new treatment options for SLE. This study aims to conduct a comparative analysis of the adverse drug events (AEs) associated with anifrolumab (Saphnelo) and belimumab (Benlysta). AEs were extracted from the FDA adverse event reporting system (FAERS) for the period from April 2011 to April 2024. A total of 21,631 cases were collected from the FAERS system (20,819 for belimumab, 812 for anifrolumab). In terms of injury, poisoning, and procedural complications, anifrolumab was more prone to infusion-related reactions (ROR 6.64), while belimumab exhibited unique AEs such as product dose omissions (ROR 12.63), improper device usage techniques (ROR 20.66), and exposure via skin contact (ROR 80.18). In the category of infections and infestations, anifrolumab was more likely to cause herpes zoster (ROR 21.91), whereas belimumab was more commonly associated with influenza (ROR 2.75). Regarding nervous system disorders, anifrolumab showed a higher incidence of headache (ROR 2.83). In skin and subcutaneous tissue disorders, anifrolumab demonstrated strong signals for rash (ROR 2.29). More severely, anifrolumab was associated with a higher risk of pericarditis (ROR 7.92). Additionally, anifrolumab may lead to psychiatric, vascular, renal, and urinary disorders, primarily presenting as confusional state (ROR 2.14), flushing (ROR 2.94), and proteinuria (ROR 10.96). The adverse reactions associated with belimumab are primarily linked to operational factors (such as product dose omissions) and injection site issues (e.g., injection site pain and hemorrhage). AE reports for anifrolumab demonstrated significant complexity and diversity. Enhanced patient monitoring and therapy optimization are urgently required to ensure more effective management of SLE while minimizing risks.
- Open Access
- 30 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (22) , e42465
Invasive ductal breast cancer with focal mucinous differentiation in a 38-year-old woman: Case report and literature review
Rationale: Breast cancer (BC) is a common malignant tumor with a poor prognosis that requires early treatment. Invasive ductal BC with focal mucinous differentiation in a 38-year-old woman is rarely reported. Patient concerns: A 38-year-old woman presented to our clinic 3 months after discovering a breast mass that had increased in size during this period. Enhanced computed tomography showed an irregular mass with lobulated edges and burrs at the 9 o’clock position on the patient’s right breast. An early enhanced scan showed significant heterogeneous enhancement with continuous enhancement. Diagnoses: The patient’s postoperative pathology suggested that the patient had an infiltrating ductal BC with focal mucinous differentiation. Interventions: The patient underwent right breast mass resection first. After the pathological diagnosis was confirmed, the patient underwent right breast resection and right axillary lymph node dissection. Outcomes: The patient’s postoperative recovery was good. To date, the patient has not experienced any symptoms of recurrence. Lessons: Owing to the poor prognosis of BC, patients with abnormal breast masses should be diagnosed and treated as soon as possible. Further prognosis research on the invasive ductal carcinoma with focal mucinous differentiation occurring in young individuals is warranted.
- 30 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (22) , e42465
Open AccessInvasive ductal breast cancer with focal mucinous differentiation in a 38-year-old woman: Case report and literature review
Rationale: Breast cancer (BC) is a common malignant tumor with a poor prognosis that requires early treatment. Invasive ductal BC with focal mucinous differentiation in a 38-year-old woman is rarely reported. Patient concerns: A 38-year-old woman presented to our clinic 3 months after discovering a breast mass that had increased in size during this period. Enhanced computed tomography showed an irregular mass with lobulated edges and burrs at the 9 o’clock position on the patient’s right breast. An early enhanced scan showed significant heterogeneous enhancement with continuous enhancement. Diagnoses: The patient’s postoperative pathology suggested that the patient had an infiltrating ductal BC with focal mucinous differentiation. Interventions: The patient underwent right breast mass resection first. After the pathological diagnosis was confirmed, the patient underwent right breast resection and right axillary lymph node dissection. Outcomes: The patient’s postoperative recovery was good. To date, the patient has not experienced any symptoms of recurrence. Lessons: Owing to the poor prognosis of BC, patients with abnormal breast masses should be diagnosed and treated as soon as possible. Further prognosis research on the invasive ductal carcinoma with focal mucinous differentiation occurring in young individuals is warranted.
- Open Access
- 17 February 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-21
Comprehensive network pharmacology and experimental study to investigate the effect and mechanism of solasonine on breast carcinoma treatment
Background: Ferroptosis is a therapeutic strategy for breast carcinoma (BC). Solasonine (SS) was linked to ferroptosis as a tumor suppressor. However, whether SS could treat BC by activating ferroptosis and its underlying mechanisms has not been reported. Methods: We obtained the intersection of genes targeting SS and BC disease through network pharmacology. Bioinformatics analysis revealed that the intersection genes were primarily enriched in the extracellular signal-regulated kinase 2/mitogen-activated protein kinase (ERK2/MAPK) signaling pathway. The interaction modes of SS with ERK2 and epidermal growth factor receptor (EGFR) were simulated by molecular docking. We further detected the expressions of ERK2 and p-ERK2 in BC patients and the correlation between ERK2/p-ERK2 and ferroptosis. The effects and mechanism of SS on ferroptosis in BC were validated by mutation plasmids construction, immunohistology, wound healing, transwell assay, and western blotting using in vitro and in vivo models. Results: ERK2 and p-ERK2 were up-regulated in BC patients, and the ERK2/p-ERK2 ratio was negatively correlated with ferroptosis. Molecular docking indicated that SS could bind to ERK2 and EGFR to inhibit the activity of the ERK2/MAPK pathway. In vitro and in vivo experiments confirmed that SS induced ferroptosis by inhibiting the ERK2/MAPK pathway, inhibiting proliferation, migration, and invasion of BC cells. Conclusion: SS could inactivate the ERK2/MAPK pathway, thereby inducing ferroptosis and further inhibiting BC cell proliferation, migration, and invasion. This study clarified the potential mechanism of SS in BC and provided a theoretical basis for its clinical application.
- 17 February 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-21
Open AccessComprehensive network pharmacology and experimental study to investigate the effect and mechanism of solasonine on breast carcinoma treatment
Background: Ferroptosis is a therapeutic strategy for breast carcinoma (BC). Solasonine (SS) was linked to ferroptosis as a tumor suppressor. However, whether SS could treat BC by activating ferroptosis and its underlying mechanisms has not been reported. Methods: We obtained the intersection of genes targeting SS and BC disease through network pharmacology. Bioinformatics analysis revealed that the intersection genes were primarily enriched in the extracellular signal-regulated kinase 2/mitogen-activated protein kinase (ERK2/MAPK) signaling pathway. The interaction modes of SS with ERK2 and epidermal growth factor receptor (EGFR) were simulated by molecular docking. We further detected the expressions of ERK2 and p-ERK2 in BC patients and the correlation between ERK2/p-ERK2 and ferroptosis. The effects and mechanism of SS on ferroptosis in BC were validated by mutation plasmids construction, immunohistology, wound healing, transwell assay, and western blotting using in vitro and in vivo models. Results: ERK2 and p-ERK2 were up-regulated in BC patients, and the ERK2/p-ERK2 ratio was negatively correlated with ferroptosis. Molecular docking indicated that SS could bind to ERK2 and EGFR to inhibit the activity of the ERK2/MAPK pathway. In vitro and in vivo experiments confirmed that SS induced ferroptosis by inhibiting the ERK2/MAPK pathway, inhibiting proliferation, migration, and invasion of BC cells. Conclusion: SS could inactivate the ERK2/MAPK pathway, thereby inducing ferroptosis and further inhibiting BC cell proliferation, migration, and invasion. This study clarified the potential mechanism of SS in BC and provided a theoretical basis for its clinical application.
- Open Access
- 8 June 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (11) , 4949-4951
Occult breast cancer with pathological complete response to neoadjuvant chemotherapy
- 8 June 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (11) , 4949-4951
Open AccessOccult breast cancer with pathological complete response to neoadjuvant chemotherapy
- Open Access
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e37246
Postoperative recurrence of diffuse sclerosing thyroid cancer in an adolescent patient: A case report
Background: Papillary thyroid cancer is an inert malignant tumor with a good response to surgical treatment, low recurrence and metastasis rate, and good prognosis. Diffuse sclerosing thyroid cancer is an invasive subtype that is more common in young people, with a higher rate of lymph node metastasis and recurrence, and a relatively poor prognosis. Patient concerns: A 13-year-old girl underwent radical surgery for diffuse sclerosing thyroid cancer. Eight years later, due to a large number of lymph node metastases, she underwent another radical surgery on her neck lymph nodes. Methods: The patient thyroid ultrasound and neck enhanced CT indicated that the patient had multiple enlarged lymph nodes in the neck with irregular morphology and structure, and the possibility of metastatic lymph nodes was high. Subsequently, the patient underwent thyroid fine-needle aspiration and the results showed that cancer cells were detected in both cervical lymph nodes. Diagnosis: The patient was diagnosed with bilateral cervical lymph node metastases after thyroid surgery. Results: After the second surgery, the patient recovered well, and no residual or focal iodine uptake tissue was found on the enhanced CT examination. Conclusion: As diffuse sclerosing thyroid cancer is prone to lymph node and recurrent metastases, once it is diagnosed, radical treatment should be actively performed. Postoperative adjuvant radiation therapy should be administered according to the patient condition and regular follow-ups should be conducted to monitor neck lymph node metastasis.
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e37246
Open AccessPostoperative recurrence of diffuse sclerosing thyroid cancer in an adolescent patient: A case report
Background: Papillary thyroid cancer is an inert malignant tumor with a good response to surgical treatment, low recurrence and metastasis rate, and good prognosis. Diffuse sclerosing thyroid cancer is an invasive subtype that is more common in young people, with a higher rate of lymph node metastasis and recurrence, and a relatively poor prognosis. Patient concerns: A 13-year-old girl underwent radical surgery for diffuse sclerosing thyroid cancer. Eight years later, due to a large number of lymph node metastases, she underwent another radical surgery on her neck lymph nodes. Methods: The patient thyroid ultrasound and neck enhanced CT indicated that the patient had multiple enlarged lymph nodes in the neck with irregular morphology and structure, and the possibility of metastatic lymph nodes was high. Subsequently, the patient underwent thyroid fine-needle aspiration and the results showed that cancer cells were detected in both cervical lymph nodes. Diagnosis: The patient was diagnosed with bilateral cervical lymph node metastases after thyroid surgery. Results: After the second surgery, the patient recovered well, and no residual or focal iodine uptake tissue was found on the enhanced CT examination. Conclusion: As diffuse sclerosing thyroid cancer is prone to lymph node and recurrent metastases, once it is diagnosed, radical treatment should be actively performed. Postoperative adjuvant radiation therapy should be administered according to the patient condition and regular follow-ups should be conducted to monitor neck lymph node metastasis.
- Open Access
- 5 January 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (4) , 1917-1918
Papillary thyroid carcinoma with parapharyngeal and pulmonary metastases: A case report and literature review
- 5 January 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (4) , 1917-1918
Open AccessPapillary thyroid carcinoma with parapharyngeal and pulmonary metastases: A case report and literature review
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Endocrinology
- Vol. 2024 (1)
Short‐Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic‐Psycho Relevance
Objective: To understand whether TSH suppressive therapy affect short‐term postoperative cancer‐related depression and anxiety among DTC patients. To evaluate short‐term postoperative psychological problems and its relationship with baseline parameters, fatigue, sleep quality, illness perception, and patients’ quality of life. Study Design and Methods: This was a prospective, observational, single center study. This study involved 831 TC patients who consecutively admitted to the inpatient department of hospital between 1st June 2020 and 31th February 2021. Results: Mean scores of the self‐rated anxiety scale (SAS) (49.04 vs. 40.69) and self‐rated depression scale (SDS) (44.61 vs. 39.86), as well as the incidence of anxiety (41.5% vs. 22.1%) and depression (22.5% vs. 2.4%) significantly decreased 3 months after surgery. For personal and clinical characteristics, low educational background (SAS, β = 1.392; SDS, β = 1.622; and p < 0.05), without children (SAS, β = 4.068; SDS, β = 1.873, and p < 0.01), FNAC (SAS, β = −0.981; SDS, β = −2.583; and p < 0.05), and multifocal tumor (SAS, β = −1.287; SDS, β = −2.681; and p < 0.05) were the main effects for both short‐term postoperative anxiety and depression. Multiple linear regression analysis identified the serum TSH level as a significant variable associated with worse SAS (Beta = −0.695 and p = 0.043) and SDS (Beta = −3.133 and p < 0.001) scores 3 months after surgery. FT4 was independently associated with SAS scores (Beta = −0.202 and p < 0.001). Patients with middle ATA risk had a significantly higher level of SDS scores (p = 0.033). Conclusion: We confirmed that cancer‐related anxiety and depression among DTC patients significantly alleviated 3 months after surgery. TSH suppression therapy has profound effects on cancer‐related anxiety and depression, and the degree of anxiety and depression significantly deteriorated with the decrease of TSH level.
- 1 January 2024
- Published by Wiley in International Journal of Endocrinology
- Vol. 2024 (1)
Open AccessShort‐Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic‐Psycho Relevance
Objective: To understand whether TSH suppressive therapy affect short‐term postoperative cancer‐related depression and anxiety among DTC patients. To evaluate short‐term postoperative psychological problems and its relationship with baseline parameters, fatigue, sleep quality, illness perception, and patients’ quality of life. Study Design and Methods: This was a prospective, observational, single center study. This study involved 831 TC patients who consecutively admitted to the inpatient department of hospital between 1st June 2020 and 31th February 2021. Results: Mean scores of the self‐rated anxiety scale (SAS) (49.04 vs. 40.69) and self‐rated depression scale (SDS) (44.61 vs. 39.86), as well as the incidence of anxiety (41.5% vs. 22.1%) and depression (22.5% vs. 2.4%) significantly decreased 3 months after surgery. For personal and clinical characteristics, low educational background (SAS, β = 1.392; SDS, β = 1.622; and p < 0.05), without children (SAS, β = 4.068; SDS, β = 1.873, and p < 0.01), FNAC (SAS, β = −0.981; SDS, β = −2.583; and p < 0.05), and multifocal tumor (SAS, β = −1.287; SDS, β = −2.681; and p < 0.05) were the main effects for both short‐term postoperative anxiety and depression. Multiple linear regression analysis identified the serum TSH level as a significant variable associated with worse SAS (Beta = −0.695 and p = 0.043) and SDS (Beta = −3.133 and p < 0.001) scores 3 months after surgery. FT4 was independently associated with SAS scores (Beta = −0.202 and p < 0.001). Patients with middle ATA risk had a significantly higher level of SDS scores (p = 0.033). Conclusion: We confirmed that cancer‐related anxiety and depression among DTC patients significantly alleviated 3 months after surgery. TSH suppression therapy has profound effects on cancer‐related anxiety and depression, and the degree of anxiety and depression significantly deteriorated with the decrease of TSH level.